Genentech Facing Class Action Over Cancer Drug Skimping
An Oklahoma hospital has accused Roche's biotechnology subsidiary Genentech Inc. of cheating providers by lying about how much of breast cancer medication Herceptin it provides in each multidose vial, according to...To view the full article, register now.
Already a subscriber? Click here to view full article